Annual Report

Overview

The report presents the Group's 2011 shift toward a focused global specialty-pharmaceutical model, including the ProStrakan acquisition and a biosimilars joint venture with FUJIFILM. Consolidated net sales declined to ¥343.7 billion following business reorganization, while the company reported record earnings. Its sustainability section also describes CSR, human-rights and labor practices, and environmental initiatives, including 244 thousand tons of CO2 emissions, 9.7% below 2005.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2011
Period: 1 January 2011 – 31 December 2011
Publication date: 1 June 2012
Language: English
Pages
File size
Restatement: Disclosed

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services